{
    "nctId": "NCT06129786",
    "briefTitle": "Overcoming Therapy Resistance in ER+ Breast Cancer Patients: a Translational Project (OVERTuRE)",
    "officialTitle": "Overcoming Therapy Resistance in ER+ Breast Cancer Patients: a Translational Project (OVERTuRE)",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 74,
    "primaryOutcomeMeasure": "To identify potential biomarkers predictive of a clinical benefit in patients receiving a first line therapy with AI/fulvestrant (+/- LH-RH analogue) in association with a CDK4/6i for luminal-like ABC.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease.\n* ER positive tumor \u2265 1%\n* HER2 negative breast cancer by FISH or IHC (IHC 0,1+, 2+ and/or FISH HER2: CEP17 ratio \\< 2.0)\n* Females, 18 years of age or older\n* Candidate to first-line endocrine therapy (LH-RH analogue for pre-menopausal women is allowed)\n* Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.\n\nExclusion Criteria:\n\n* Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.\n* Prior endocrine therapy for metastatic disease\n* Prior chemotherapy for metastatic disease\n* Patients unwilling to or unable to comply with the protocol.\n* Known CNS metastases",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}